E-drug: Re: Evidence-based drug information (cont'd)
----------------------------------------------------------
Dear Prof Shoukhov,
I recently had the opportunity to attend a course in pharmacoeconomics in a
developed country. During this course, it became evident that, unless a
proper search is conducted with regard to the identification and selection
of accredited publications/non-publications, any effort to successfully
establish
the cost-effectiveness and inclusion/exclusion of a pharmaceutical for a
specific population, decisions are bound to be biased. Also, the skill to
critically assess documents have to be acquired. Only after having
established and confirmed the effectiveness of an agent, the cost
implication is established.
In developed countries the above tool is used to set prices for different
agents, whereas in developing (such as ours) countries, (the way I see it):
- Collect relevant epidemiological information
- Set priorities
- Effectively allocate limited resources according to priorities
- Establish cost implications of different treatment regimens
I hope the above information is helpful- shout if you need specific
information.
Kind regards
Leona Coetzer
Ms Leona Coetzer, pharmacist
snailmail: Hallmark 1008, P/Bag X 828, Pretoria 0001, South Africa
Tel +27-12-3120339, Fax +27-12-3287585, Email ppc@comed.pwv.gov.za
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.